New partnership leverages Google’s infrastructure and artificial intelligence capabilities.
Medable has announced a collaboration with Google Cloud to bring its Digital and Decentralized Clinical Trial Platform to Google Cloud Marketplace. Customers of Medable will benefit from Google’s infrastructure and artificial intelligence capabilities with accelerated operations in clinical trial design, deployment, and management.1
In a press release, Michelle Longmire, MD co-founder and CEO of Medable said, “This alliance provides life sciences companies with Medable’s cutting-edge clinical development technology powered by Google Cloud through Google Cloud Marketplace. The collaboration will enable scaled and seamless adoption of Medable solutions by Google Cloud users, providing life sciences companies with platform capabilities proven to improve patient access to trials and accelerate critical development efforts, globally.”
In addition to its Digital and Decentralized Clinical Trial Platform, Medable’s newly launched Studio will integrate seamlessly with Google Cloud Marketplace.
“Bringing Medable’s platform to Google Cloud Marketplace will help customers quickly deploy, manage, and expand their use of the AI-driven clinical trial platform on Google Cloud's trusted, global infrastructure," Dai Vu, managing director, marketplace & ISV GTM programs at Google Cloud, said in the press release.
Medable Studio was introduced earlier in August. The application offers customers an all-in-one solution for electronic clinical outcome assessment (eCOA) management. It has capabilities in configuration, translation, and validation throughout the eCOA launch process. Customers of Studio can choose between self-service, full-service, or a combination of options.2
“Medable Studio upends the traditional study build/test/launch process by streamlining it using intelligence and automation,” Tim Smith, chief technology officer and co-founder, Medable, said in an earlier press release. “With Medable Studio, timelines shift from weeks and months to just days. Customers described Studio as a quantum leap in speed, scale, and quality, and it empowers sponsors with complete visibility and control over the entire process.”
Functions of Studio include:
In the press release, Longmire added, “This is just the start to transforming how evidence is generated. Medable Studio is where trial teams go to create. It allows for greater scalability, efficiency gains, and better, protocol-fit science. Studio will set new benchmarks for trial execution and ultimately advance our mission to enable effective therapies to reach patients faster by reducing trial start-up timelines and cost.”
1. Medable Joins Forces with Google Cloud to Deliver Digital Clinical Trials Technology on Google Cloud Marketplace. News release. Medable. October 30, 2024. Accessed November 1, 2024. https://www.businesswire.com/news/home/20241030519844/en/Medable-Joins-Forces-with-Google-Cloud-to-Deliver-Digital-Clinical-Trials-Technology-on-Google-Cloud-Marketplace
2. New Medable Studio Empowers Sponsors to Launch eCOA Solutions Into Clinical Trials With Unparalleled Control and Efficiency. News release. Medable. August 14, 2024. Accessed November 1, 2024. https://www.businesswire.com/news/home/20240814443065/en/New-Medable-Studio-Empowers-Sponsors-to-Launch-eCOA-Solutions-Into-Clinical-Trials-With-Unparalleled-Control-and-Efficiency
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.